Show simple item record

dc.contributor.authorBernal, D.
dc.contributor.authorBereznicki, L.
dc.contributor.authorStafford, Leanne
dc.contributor.authorCastelino, R.
dc.contributor.authorThompson, A.
dc.contributor.authorDavidson, P.
dc.contributor.authorPeterson, G.
dc.identifier.citationBernal, D. and Bereznicki, L. and Stafford, L. and Castelino, R. and Thompson, A. and Davidson, P. and Peterson, G. 2016. Medication Adherence Following Acute Coronary Syndrome: Does One Size Fit All?. American Journal of Cardiovascular Drugs. 16 (1): pp. 9-17.

© 2015, Springer International Publishing Switzerland.Guideline-based management of acute coronary syndrome (ACS) is well established, yet some may challenge that strict implementation of guideline recommendations can limit the individualization of therapy. The use of all recommended medications following ACS places a high burden of responsibility and cost on patients, particularly when these medications have not been previously prescribed. Without close attention to avoiding non-adherence to these medications, the full benefits of the guideline recommendations will not be realized in many patients. Using a case example, we discuss how the recognition of adherence barriers can be an effective and efficient process for identifying patients at risk of non-adherence following ACS. For those identified as at risk, the World Health Organization’s model of adherence barriers is explored as a potentially useful tool to assist with individualization of therapy and promotion of adherence.

dc.publisherAdis International Ltd.
dc.titleMedication Adherence Following Acute Coronary Syndrome: Does One Size Fit All?
dc.typeJournal Article
dcterms.source.titleAmerican Journal of Cardiovascular Drugs
curtin.accessStatusFulltext not available

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record